Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

医学 骨膜炎 哮喘 安慰剂 恶化 内科学 临床终点 支气管扩张剂 生物标志物 嗜酸性粒细胞 喘息 呼出气一氧化氮 随机对照试验 肺活量测定 病理 细胞外基质 化学 替代医学 细胞生物学 生物 生物化学
作者
Nicola A. Hanania,Phillip E. Korenblat,Kenneth R. Chapman,Eric D. Bateman,Petr Kopecký,Pierluigi Paggiaro,Akihito Yokoyama,Julie Olsson,Sarah Gray,Cécile Holweg,Mark D. Eisner,Charles Asare,Saloumeh K Fischer,Kun Peng,Wendy S. Putnam,John G. Matthews
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:4 (10): 781-796 被引量:445
标识
DOI:10.1016/s2213-2600(16)30265-x
摘要

Background In phase 2 trials, lebrikizumab, an anti-interleukin-13 monoclonal antibody, reduced exacerbation rates and improved FEV1 in patients with uncontrolled asthma, particularly in those with high concentrations of type 2 biomarkers (eg, periostin or blood eosinophils). We undertook replicate phase 3 studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma despite inhaled corticosteroids and at least one second controller medication. Methods Adult patients with uncontrolled asthma, pre-bronchodilator FEV1 40–80% predicted, and stable background therapy were randomly assigned (1:1:1) with an interactive voice–web-based response system to receive lebrikizumab 37·5 mg or 125 mg, or placebo subcutaneously, once every 4 weeks. Randomisation was stratified by screening serum periostin concentration, history of asthma exacerbations within the last 12 months, baseline asthma medications, and country. The primary efficacy endpoint was the rate of asthma exacerbations over 52 weeks in biomarker-high patients (periostin ≥50 ng/mL or blood eosinophils ≥300 cells per μL), analysed with a Poisson regression model corrected for overdispersion with Pearson χ2 that included terms for treatment group, number of asthma exacerbations within the 12 months before study entry, baseline asthma medications, geographic region, screening periostin concentration, and blood eosinophil counts as covariates. Both trials are registered at ClinicalTrials.gov, LAVOLTA I, number NCT01867125, and LAVOLTA II, number NCT01868061. Findings 1081 patients were treated in LAVOLTA I and 1067 patients in LAVOLTA II. Over 52 weeks, lebrikizumab reduced exacerbation rates in biomarker-high patients in the 37·5 mg dose group (rate ratio [RR] 0·49 [95% CI 0·34–0·69], p<0·0001) and in the 125 mg dose group (RR 0·70 [0·51–0·95], p=0·0232) versus placebo in LAVOLTA I. Exacerbation rates were also reduced in biomarker-high patients in both dose groups versus placebo in LAVOLTA II (37·5 mg: RR 0·74 [95% CI 0·54–1·01], p=0·0609; 125 mg: RR 0·74 [0·54–1·02], p=0·0626). Pooling both studies, the proportion of patients who experienced treatment-emergent adverse events (79% [1125 of 1432 patients] for both lebrikizumab doses vs 80% [576 of 716 patients] for placebo), serious adverse events (8% [115 patients] for both lebrikizumab doses vs 9% [65 patients] for placebo), and adverse events leading to study drug discontinuation (3% [49 patients] for both lebrikizumab doses vs 4% [31 patients] for placebo) were similar between lebrikizumab and placebo. The following serious adverse events were reported in the placebo-controlled period: one event of aplastic anaemia and five serious adverse events related to raised concentrations of eosinophils in patients treated with lebrikizumab and one event of eosinophilic pneumonia in the placebo group. Interpretation Lebrikizumab did not consistently show significant reduction in asthma exacerbations in biomarker-high patients. However, it blocked interleukin-13 as evidenced by the effect on interleukin-13-related pharmacodynamic biomarkers, and clinically relevant changes could not be ruled out. Funding F Hoffmann-La Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
keeno完成签到,获得积分10
1秒前
nicewink发布了新的文献求助10
2秒前
星河梦枕完成签到,获得积分10
3秒前
pluto完成签到,获得积分20
3秒前
小张发布了新的文献求助30
4秒前
dengdengdeng发布了新的文献求助10
4秒前
4秒前
愉快幻悲完成签到,获得积分10
6秒前
ecoli发布了新的文献求助10
6秒前
周奕迅发布了新的文献求助10
7秒前
小宝爸爸发布了新的文献求助10
8秒前
yang完成签到,获得积分10
9秒前
慕青应助灰底爆米花采纳,获得10
9秒前
852应助nicewink采纳,获得10
10秒前
dengdengdeng完成签到,获得积分10
11秒前
叮当发布了新的文献求助10
12秒前
bkagyin应助keyanrubbish采纳,获得30
14秒前
xtt完成签到,获得积分10
16秒前
Aimee完成签到 ,获得积分10
18秒前
18秒前
小马甲应助Arui采纳,获得10
18秒前
大个应助hg08采纳,获得10
20秒前
21秒前
DELI完成签到 ,获得积分10
22秒前
隐形曼青应助科研通管家采纳,获得10
23秒前
酷波er应助科研通管家采纳,获得10
23秒前
YamDaamCaa应助科研通管家采纳,获得30
23秒前
ED应助科研通管家采纳,获得10
23秒前
大模型应助科研通管家采纳,获得10
23秒前
科研通AI2S应助科研通管家采纳,获得10
23秒前
搜集达人应助科研通管家采纳,获得10
23秒前
kecheng应助科研通管家采纳,获得10
23秒前
YamDaamCaa应助科研通管家采纳,获得30
23秒前
23秒前
23秒前
23秒前
orixero应助sss采纳,获得10
25秒前
25秒前
周奕迅完成签到,获得积分20
27秒前
mashichuang发布了新的文献求助10
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Indomethacinのヒトにおける経皮吸収 400
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 370
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
Current Perspectives on Generative SLA - Processing, Influence, and Interfaces 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3991794
求助须知:如何正确求助?哪些是违规求助? 3532981
关于积分的说明 11260197
捐赠科研通 3272241
什么是DOI,文献DOI怎么找? 1805664
邀请新用户注册赠送积分活动 882609
科研通“疑难数据库(出版商)”最低求助积分说明 809405